Relmada Announces FDA Acceptance of IND and Authorization to Commence Phase 2a Clinical Trial for d-Methadone

By WebmasterJanuary 25, 2017November 1st, 2024No Comments

Relmada Announces FDA Acceptance of IND and Authorization to Commence Phase 2a Clinical Trial for d-Methadone

Previous PostOssianix receives milestone payment from Lundbeck for blood-brain barrier (BBB) antibody delivery technology
Next PostOptofluidics announces Hexpoint, a new particle analysis system for early stage formulation